# Yongsheng Buluo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yongsheng-buluo

- Industry: Biotechnology
- Headquarters: Huangshan, China
- Latest round: Angel (Apr 15, 2025)
- Investors on record: 2

## About

Based in Huangshan, China, and founded in 2024, Yongsheng Buluo is a developer of new immune cell and stem cell drugs. Its core founding team members all come from Tsinghua Bio and Beijing 301 Hospital. In April 2025, it closed an angel funding co-led by new investors JHF Investment and Prosperity Investment.

Yongsheng Buluo focuses on the research and development of new immune cell and stem cell drugs, and focuses on the development of a universal CAR-NK cell platform targeting solid tumors. It provides gene-edited cell therapy drugs, tumor mRNA vaccines and organ regeneration for cancer patients.

The company generates revenue by developing new drugs for immune cells and stem cells.

The company will use the fund to build a stem cell laboratory and clinical transformation of the patented CAR-NK immune cell lung cancer treatment technology.

## Funding rounds

- Angel, Apr 15, 2025 — JHF Investment, Prosperity Investment

## Investors

- JHF Investment (https://capitalatlas.ai/funds/jhf-investment) — Angel
- Prosperity Investment — Angel